scholarly journals Early cost-effectiveness analysis of risk-based selection strategies for adjuvant treatment in stage II colon cancer: the potential value of prognostic molecular markers

2021 ◽  
pp. cebp.0078.2021
Author(s):  
Gabrielle Jongeneel ◽  
Marjolein JE Greuter ◽  
Natalia Kunst ◽  
Felice N van Erning ◽  
Miriam Koopman ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Molecular Markers ◽  
Cost Effectiveness ◽  
Adjuvant Treatment ◽  
Cost Effectiveness Analysis ◽  
Stage Ii ◽  
Potential Value ◽  
Selection Strategies ◽  
Effectiveness Analysis ◽  
Stage Ii Colon Cancer

Cost-effectiveness analysis of oxaliplatin/5-FU/LV in adjuvant treatment of stage III colon cancer in the U.S

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 3532-3532 ◽  
Author(s):  
S. Aballea ◽  
J. Chancellor ◽  
M. Raikou ◽  
M. Drummond ◽  
M. Weinstein ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cost Effectiveness ◽  
Adjuvant Treatment ◽  
Cost Effectiveness Analysis ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Effectiveness Analysis ◽  
The U.S

scholarly journals Model-based effectiveness and cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy in Dutch stage II colon cancer patients

2021 ◽  
Vol 14 ◽  
pp. 175628482199571
Author(s):  
Gabrielle Jongeneel ◽  
Marjolein J. E. Greuter ◽  
Felice N. van Erning ◽  
Miriam Koopman ◽  
Geraldine R. Vink ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cost Effectiveness ◽  
Adjuvant Chemotherapy ◽  
Stage Ii ◽  
Dutch Guideline ◽  
Selection Strategies ◽  
Life Years ◽  
Stage Ii Colon Cancer ◽  
Perfect Adherence ◽  
Selection Of

Background: We aimed to evaluate the cost-effectiveness of risk-based strategies to improve the selection of surgically treated stage II colon cancer (CC) patients for adjuvant chemotherapy. Methods: Using the ‘Personalized Adjuvant TreaTment in EaRly stage coloN cancer’ (PATTERN) model, we evaluated five selection strategies: (1) no chemotherapy, (2) Dutch guideline recommendations assuming observed adherence, (3) Dutch guideline recommendations assuming perfect adherence, (4) biomarker mutation OR pT4 stage strategy in which patients with MSS status combined with a pT4 stage or a mutation in BRAF and/or KRAS receive chemotherapy assuming perfect adherence and (5) biomarker mutation AND pT4 stage strategy in which patients with MSS status combined with a pT4 stage tumor and a BRAF and/or KRAS mutation receive chemotherapy assuming perfect adherence. Outcomes were number of CC deaths per 1000 patients and total discounted costs and quality-adjusted life-years (QALYs) per patient (pp). Analyses were conducted from a societal perspective. The robustness of model predictions was assessed in sensitivity analyses. Results: The reference strategy, that is, no adjuvant chemotherapy, resulted in 139 CC deaths in a cohort of 1000 patients, 8.077 QALYs pp and total costs of €22,032 pp. Strategies 2–5 were more effective (range 8.094–8.217 QALYs pp and range 118–136 CC deaths per 1000 patients) and more costly (range €22,404–€25,102 pp). Given a threshold of €50,000/QALY, the optimal use of resources would be to treat patients with either the full adherence strategy and biomarker mutation OR pT4 stage strategy. Conclusion: Selection of stage II CC patients for chemotherapy can be improved by either including biomarker status in the selection strategy or by improving adherence to the Dutch guideline recommendations.

scholarly journals Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US

Cancer ◽  
2007 ◽  
Vol 109 (6) ◽  
pp. 1082-1089 ◽  
Author(s):  
Samuel Aballéa ◽  
Jeremy V.M. Chancellor ◽  
Maria Raikou ◽  
Michael F. Drummond ◽  
Milton C. Weinstein ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cost Effectiveness ◽  
Adjuvant Treatment ◽  
Cost Effectiveness Analysis ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Effectiveness Analysis ◽  
The Us
Sign in / Sign up

Export Citation Format

Share Document